Dietrich Stephan

Dietrich Stephan

Director/Board Member at
Epistemix, Inc.

Net worth: 144 944 $ as of 31/10/2026

56 year
Consumer Services
Health Technology
Commercial Services

Profile

Dietrich A. Stephan was the founder of Amnestix, Inc. (founded 2006), serving as Director-Neurogenomics Division; Life Technologies Clinical Services Lab, Inc. (founded 2006), serving as Director & Chief Science Officer from 2007 to 2011; Lifecode, Inc. (founded 2011), serving as President, Chief Executive Officer & Director from 2011 to 2015; and NeuBase Therapeutics, Inc. (founded 2009), serving as Chief Executive Officer & Director from 2022 to 2024.
Dr. Stephan is also the founder of DiaVacs, Inc.,LifeX Holdings LLC..
Dr. Stephan currently serves as Chairman-Neuroscience Microarray Consortium at the National Institutes of Health since 2011; Independent Director at Sharp Therapeutics Corp.
since 2024; Director at FRX Growth Partners LLC; Director at Epistemix, Inc.; Member at National Institute of Health Policy; and Managing Partner at Cyto Ventures since 2018.
Former positions include President & Chief Executive Officer at Neubase Therapeutics, Inc.; Chairman-Human Genetics Department & Professor at the University of Pittsburgh; Chairman-Neurogenomics Department & Professor at Translational Genomics Research Institute; Chairman at Pendulum, Inc.; Chairman at Peptilogics, Inc. from 2016 to 2025; Director at Western Oncolytics Ltd.; Executive Director-Gene Partnership at The Children's Hospital Corp.
and Harvard Medical School; Director at Personalized Medicine Coalition, Sharp Edge Labs, Inc., iGenomX International Genomics LLC, Parabase Genomics, Inc., Ariel Precision Medicine, Inc., CereDx, Inc.; Director at Pendulum Therapeutics, Inc. from 2012 to 2018; Faculty Member at George Washington University, Arizona State University, The Johns Hopkins University, and the University of Arizona; and Chief Science Advisor at FarmaceuticalRX LLC.
Education includes undergraduate studies at Carnegie Mellon University and a doctorate from the University of Pittsburgh Graduate School of Public Health.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
0.77%
21/05/2025 2,41,574 ( 0.77% ) 144 944 $ 31/10/2026

Dietrich Stephan active positions

CompaniesPositionStart
Director/Board Member -
Director/Board Member -
National Institute of Health Policy
Corporate Officer/Principal -
Corporate Officer/Principal 26/07/2011
Cyto Ventures
Corporate Officer/Principal 01/01/2018

Former positions of Dietrich Stephan

CompaniesPositionEnd
Chairman 01/03/2025
NEUBASE THERAPEUTICS, INC. Chief Executive Officer 16/01/2024
Director/Board Member 01/08/2018
Founder 01/04/2011
░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░ ░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
See the detail of Dietrich Stephan's experience

Education of Dietrich Stephan

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

69

1st degree connections

33

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies33

Consumer Services

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Consumer Services

Consumer Services

Health Services

Government

Commercial Services

Health Services

National Institute of Health Policy

Consumer Services

Commercial Services

Commercial Services

Technology Services

Consumer Services

Health Technology

Commercial Services

Health Services

Health Services

Health Technology

Process Industries

Health Technology

Process Industries

Health Technology

LifeX Holdings LLC

Cyto Ventures

Commercial Services

Pendulum, Inc.

Technology Services

  1. Stock Market
  2. Insiders
  3. Dietrich Stephan